agm, page-61

Patrys has always been set for big things it's been frustrating but the irony of how it stands now in it's 6th year. It was a very exciting listing BUT all it was listing with was preclinical molecules and snaring $25M cash on listing. Now though 6 years later markets value it at $12M despite the objectives on listing being achieved with 3 drugs now in the clinic one set for out-licensing and another with Phase II data fast approaching, plenty more still pre-clinical and yet a market cap of a measly $12M ?! despite such significant progress and looking at the pointy end. It's got plenty more heads up than most though despite being one of the cheapest bios left outside of markets fanfare in that Oncology still remains the cheese for big pharma, it's like kids & candy. While the ASX has a good number of junior biotechs advancing and in Phase II trials they are all focussed on niche markets which hold many benefits but still not the breadth of oncology. My gut tip still says Patrys will be the first oz bio to get swooped by big pharma.